balance is sustained over a period of time, the excess energy is stored as fat and obesity is observed.
result in a positive energy balance and fat accretion. Therapeutic agents are needed that will address these anomalies with the goal of normalizing body weight and composition.
Appetite suppressant drugs that address the problem of hyperphagia have been reviewed in part by Bray and others (1, 2) . The present review presents the findings of researchers studying the effects of dehydroepiandrosterone (A5-androsten 3 hydroxy 17-one, DHEA)' on body fatness in genetically obese and lean rodents and in humans. Other processes have been studied as well to develop an understanding of how this steroid could serve as an antiobesity agent. Although mitially thought to inhibit the activity of glucose 6-phosphate dehydrogenase (G6PD), its mode of action is now thought to be far less specifIc.
BACKGROUND
DHEA is a metabolic intermediate in the pathway for the synthesis of testosterone, estrone, and estracliol ( Fig. 1) . The pathway has a common precursor, cholesterol, which is converted to pregnenolone via the P450 enzymes,
20,22-hydroxylase
or 20,22-desmolase. Pregnenolone is also the precursor for the synthesis of the glucocorticoids, corticosterone and cortisol, as well as the mineralcorticoid aldosterone.
In humans, the complete pathway is found in the adrenals (4-6).
In rodents, however, the 17-hydroxylase (indicated as enzyme b in Fig. 1 ) is missing (7). Adrenal glands isolated from rats and mice and stimulated with ACTH release appreciable amounts of corticosterone to the media but no detectable amounts of DHEA. In humans, DI-IEA is released into the circulation as a sulfate conjugate (DHEA-S). About 99% of the circulating DHEA is in the sulfate form in this species. DHEA-S is the most abundant steroid in the bloodstream of humans.
Levels of plasma DHEA and DHEA-S are influenced by age (6, 8, 9) , physiological status (10-12), and genetics (13). Neonates and adolescents have high levels of DHEA and DHEA-S that decline with age. Low levels of the steroids have been reported in females with anorexia nervosa (10), high body mass indices (11), and breast cancer (12). Studies of families showed remarkable similarities in steroid hormone levels when age was factored out of the analysis (13). in animals from each of these strains and this improvement was attributed to an increased sensitivity of the adipocytes to insulin.
ANTIOBESITY EFFECTS
Likely this change in sensitivity was due to the decrease in fat cell size as shown by Tagliaferro et al. (22) and Muller and Cleary (24). With the increase in target cell sensitivity to insulin and decline in blood glucose, the pancreatic islet insulin stores were conserved, which explains the observation of increases in pancreatic insulin content and decreases in plasma insulin levels in these strains of rodents. A direct effect of DHEA on the pancreas was ruled out because DHEA had no effect on pancreatic insulin stores in normal mice made diabetic through the use of the 13cell cytotoxic agent, streptozotocin. It is not likely, therefore, that high levels of DHEA would be in circulation of rodents. In rats or mice treated with "pharmacological" levels of this steroid, their bodies would be responding to abnormal levels of DHEA. In response to this abnormal steroid load they probably increase their P450 detoxification activity.
The changes in metabolic flux patterns that probably are energy wasting are presented schematically in Fig. 3 . We hypothesize that these small changes in metabolism are additive and result in a decrease in energy stored as fat. Because several of these pathways are unique to the liver, this organ serves a pivitol role in regulating energy balance when the animal is treated with DHEA. Any genetically determined difference in hepatic metabolism or hepatic metabolic control would affect the degree to which the liver serves in this capacity. Hence, strain differences in response to DHEA would occur and these have been reported. results. In one, oral administration of DHEA (1600 mg/ day) for 4 wk to obese men had no effect on body fatness (63). In another, 4 wk of DHEA treatment (same dose) had no effect on either energy or protein metabolism in normal healthy subjects (64). In contrast, a study by Nestler et al. (65) Montanini, V., Simoni, M., Chiossi, C., Baraghini, G. F., Velarde, A., Baraldi, E., and Marrama, P. Effects of dehydroepiandrosterone treatment in rats with diet induced obesity. J. Nutr. 120, 1103 Nutr. 120, -1114 21. MacEwen, E. G., Kurzman, I. D., and Haifa, A. L M. (1989) EndocrinoL & Metab. 66, [57] [58] [59] [60] [61] 
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